Adaptive Therapies for Autoimmune Disease in Specialized Environments

This inventive concept adapts the original patent's approach to treating autoimmune disease by targeting pathogenic age-associated B cells, tailoring the therapy to specific operational environments, such as high-altitude settings, extreme weather conditions, disaster relief scenarios, high-security needs, and areas with poor air quality.

The original patent disclosed a method for treating autoimmune disease by targeting pathogenic age-associated B cells. However, this approach may not be effective in specific environments where immune responses are altered or challenged. This inventive concept addresses the limitations of the original patent by providing specialized variations of the therapy tailored to these unique environments.

The new inventive concept comprises a system and method for treating autoimmune disease in subjects exposed to high-altitude environments, extreme weather conditions, disaster relief settings, high-security needs, and areas with poor air quality. The system includes a therapeutically effective amount of a nucleic acid encoding human DEF6 protein and a nucleic acid encoding human SWAP-70 protein. The administration of the nucleic acids is tailored to the specific immune response challenges of each environment. For example, in high-altitude environments, the administration may be timed to coincide with periods of increased immune response. In disaster relief settings, the detection method for pathogenic age-associated B cells is adapted for use in remote or resource-limited settings.

The new inventive concept's novelty lies in its adaptation of the original patent's approach to specific operational environments, which requires a deep understanding of the immune response challenges posed by these environments. The inventive step lies in the tailored administration of the nucleic acids to address these challenges, which is not obvious from the original patent.

Alternative embodiments of the inventive concept could include adapting the therapy to other specialized environments, such as space exploration or high-stress occupations. Variations of the detection method for pathogenic age-associated B cells could be developed for use in different settings, such as clinical laboratories or point-of-care devices.

The inventive concept has significant commercial potential in the biotechnology and pharmaceutical industries, particularly in the areas of autoimmune disease treatment and personalized medicine. The target market includes healthcare providers, research institutions, and government agencies operating in specialized environments.